COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.
Anna M AcostaAdria L MathisDaniel S BudnitzAndrew I GellerShua J ChaiNisha B AldenJames MeekLarry J AndersonPatricia RyanSue KimKathryn Como-SabettiSalina TorresElizabeth DufortNancy M BennettLaurie M BillingMelissa SuttonH Keipp TalbotAndrea GeorgeHuong PhamAron J HallAlicia FryShikha GargLindsay KimPublished in: Open forum infectious diseases (2020)
Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.